Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Shu

Showing results (21-30 of 210) with videos related to

Pageof 21
Sort By:
Cellular Immunology|August 1, 1996
Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumorsG E Plautz, M Inoue, S Shu
Cancer Research|October 15, 1996
Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cellsM Inoue, G E Plautz, S Shu
Cancer Research|November 14, 1997
Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cellsL Peng, S Shu, J C Krauss
Cancer Research|March 1, 1987
In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in miceS Shu, T Chou, S A Rosenberg
Cellular Immunology|May 25, 1997
Treatment of subcutaneous tumor with adoptively transferred T cellsL Peng, S Shu, J C Krauss
Ethnicity & Health|June 5, 2001
Cognitive-behavioural therapy for the management of sickle cell disease pain: identification and assessment of costsV J Thomas, R Gruen, S Shu
Cancer Immunology, Immunotherapy : CII|November 1, 1995
Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cellsA Aruga, S Shu, A E Chang
Journal of Immunology (Baltimore, Md. : 1950)|July 15, 1991
Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2H Yoshizawa, A E Chang, S Shu
Cellular Immunology|August 1, 1990
Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicityK Sakai, A E Chang, S Shu
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1986
In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cellsS Shu, T Chou, S A Rosenberg
Pageof 21

Showing results (21-30 of 210) with videos related to

Sort By:
Pageof 21
Cellular Immunology|August 1, 1996
Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumorsG E Plautz, M Inoue, S Shu
Cancer Research|October 15, 1996
Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cellsM Inoue, G E Plautz, S Shu
Cancer Research|November 14, 1997
Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cellsL Peng, S Shu, J C Krauss
Cancer Research|March 1, 1987
In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in miceS Shu, T Chou, S A Rosenberg
Cellular Immunology|May 25, 1997
Treatment of subcutaneous tumor with adoptively transferred T cellsL Peng, S Shu, J C Krauss
Ethnicity & Health|June 5, 2001
Cognitive-behavioural therapy for the management of sickle cell disease pain: identification and assessment of costsV J Thomas, R Gruen, S Shu
Cancer Immunology, Immunotherapy : CII|November 1, 1995
Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cellsA Aruga, S Shu, A E Chang
Journal of Immunology (Baltimore, Md. : 1950)|July 15, 1991
Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2H Yoshizawa, A E Chang, S Shu
Cellular Immunology|August 1, 1990
Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicityK Sakai, A E Chang, S Shu
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1986
In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cellsS Shu, T Chou, S A Rosenberg
Pageof 21